X4 Pharmaceuticals
XFOR
X4 Pharmaceuticals (XFOR) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wells Fargo | Initiated Coverage | Overweight | $11.00 | Jul 10, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $12.00 | Jun 2, 2026 |
| Guggenheim | Initiated Coverage | Buy | $12.00 | Mar 9, 2026 |
| Stifel | Maintained | Buy | $10.00 from $7.50 | Dec 5, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 from $3.50 | Nov 10, 2025 |
| Stifel | Maintained | Buy | $9.00 from $30.00 | Aug 29, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $3.50 from $7.00 | Aug 13, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 from $1.50 | May 2, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $1.50 | Mar 27, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | $3.00 | Mar 26, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $1.50 | Feb 7, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $1.50 | Jan 14, 2025 |
| Stifel | Maintained | Buy | $4.00 from $5.00 | Nov 14, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $1.50 from $5.00 | Nov 14, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 | Jun 28, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $5.00 | May 31, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 from $3.00 | Apr 30, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $3.00 | Mar 22, 2024 |
| B. Riley Securities | Downgraded | Buy → Neutral | $1.00 from $3.00 | Dec 12, 2023 |
| HC Wainwright & Co. | Maintained | Buy | $3.00 | Aug 11, 2023 |
Frequently asked questions
What is the latest analyst rating on XFOR?
On Jul 10, 2026, Wells Fargo initiated coverage of X4 Pharmaceuticals at Overweight with a price target of $11.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.